Shilpa Medicare Signs Long-Term Manufacturing and Development Pact with NXI Therapeutics AG
Shilpa Medicare and NXI Therapeutics AG have entered into a long-term agreement to support development and commercial manufacturing of immunomodulatory therapies, expanding Shilpa’s global CDMO footprint in high-growth biologics and specialty therapeutics.
Pharmaceutical Manufacturing Collaboration | 14/05/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy